vedolizumab

Type: Keyphrase
Name: vedolizumab
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

Top medicine articles for July 2014

A collection of some interesting medical articles published recently: Migraines Linked to Increased Risk of 'Silent Strokes' http://buff.ly/1hTE5Ru Doctor’s Salaries Are Not the Big Cost - NYTimes http://buff.ly/QWe2lx  -- "There is a startling ... [Published Clinical Cases and Images: CasesBlog - Jul 23 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

MRC Technology Announces Humanization of Anti-Tau Monoclonal Antibody for Alzheimer’s Disease Therapy

Antibody inhibits Tau aggregation involved in the pathology of Alzheimer’s and other neurodegenerative diseasesMRC Technology, a technology transfer organisation, announced today that it has successfully humanized an anti-tau monoclonal antibody, which ... [Published Select Science - Jul 22 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

New, broad-spectrum UC treatments available, in pipeline

It’s an “interesting time” in treatment options and advances in ulcerative colitis, according to William J. Sandborn, MD, chief of the Division of Gastroenterology at the University of California, San Diego.A broad range of treatment options have become ... [Published Orthopedics Today - Jul 18 2014]
First reported Jul 16 2014 - Updated Jul 16 2014 - 1 reports

European Medicines Agency recommends 39 medicines for human use for marketing authorisation in first half of 2014

Thirty-nine medicines for human use were recommended for marketing authorisation by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) in the first half of 2014, compared with 44 in first half of 2013 and 33 in first ... [Published PharmaNews.eu - Jul 16 2014]
First reported Jul 10 2014 - Updated Jul 11 2014 - 1 reports

EMA: 39 human-use drug OKs in first-half 2014

The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) recommended 39 human-use medicines for marketing authorisation in first-half 2014, compared to 44 in the same period of 2013 and 33 in first-half 2012. However, ... [Published Pharma Times - Jul 10 2014]
First reported Jul 08 2014 - Updated Jul 09 2014 - 3 reports

Takeda's Entyvio available in UK for UC and Crohn's

UK patients with ulcerative colitis and Crohn's disease can now potentially get access to Takeda UK's Entyvio following the drug's launch in the country.In May, Entyvio (vedolizumab) became the first and only biologic therapy to be approved in Europe ... [Published Pharma Times - Jul 09 2014]
First reported Jul 08 2014 - Updated Jul 08 2014 - 2 reports

Treatment for ulcerative colitis and Crohn’s disease launched

A new drug treatment for ulcerative colitis and Crohn’s disease has been launched in the UK.Vedolizumab is a gut-selective integrin antagonist, marketed as Entyvio by Takeda UK. It will be used to treat patients with active ulcerative colitis or active ... [Published Pharmacy Magazine - Jul 08 2014]
First reported Jun 16 2014 - Updated Jun 16 2014 - 2 reports

Entyvio available in US for treating ulcerative colitis, Crohn's disease

Takeda Pharmaceuticals announced today that Entyvio is now commercially available to US health care providers for the treatment of moderate to severe ulcerative colitis and Crohn’s disease in adult patients, according to a press release.The announcement ... [Published Orthopedics Today - Jun 16 2014]
First reported May 26 2014 - Updated May 28 2014 - 2 reports

Takeda Receives European Commission Marketing Authorisation for Entyvio(R) (vedolizumab) for the Treatment of Ulcerative Colitis and Crohn’s Disease

Zurich And Osaka, Japan (ots/PRNewswire) – Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission (EC) has granted Marketing Authorisation for Entyvio(R) ... [Published PRESSEMITTEILUNGEN - May 27 2014]
First reported May 23 2014 - Updated May 23 2014 - 1 reports

ENTYVIO (Vedolizumab) Injection, Powder, Lyophilized, For Solution [Takeda Pharmaceuticals America, Inc.]

First reported May 20 2014 - Updated May 21 2014 - 3 reports

Takeda's Entyvio gets FDA approval to treat ulcerative colitis, Crohn's disease

Japan-based Takeda Pharmaceutical Company (Takeda) and its wholly-owned subsidiary Takeda Pharmaceuticals USA have received approval from the US Food and Drug Administration (FDA) for a new biologic therapy, Entyvio (vedolizumab), to treat adults with ... [Published PBR - News - May 21 2014]
First reported May 20 2014 - Updated May 21 2014 - 2 reports

FDA Approves Takeda's Entyvio™ (vedolizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

DEERFIELD, Ill. and OSAKA, Japan, May 20, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States (U.S.) Food and Drug Administration ... [Published PR Newswire: Policy & Public Interest - May 20 2014]

Quotes

..." 25% of US adults consult online physician-rating sites - Doctors Check Online Ratings From Patients and Make Changes. Online ratings "can be pretty brutal. However, part of being a physician now is having to deal with these.” "When we decided to quit ignoring it and embraced it, it totally changed the game" - WSJ http://buff.ly/1mQ5XLC FDA Approves New Drug for Crohn Disease and UC: vedolizumab (Entyvio) , an injectable monoclonal antibody. Vedolizumab, an integrin receptor antagonist http://buff.ly/1lFuRtv Interferon-free regimen with 3 drugs effective in Hep C with Cirrhosis (ABT-450/r–Ombitasvir, Dasabuvir, Ribavirin) http://buff.ly/1o8pDMS -- Combination of nucleotide polymerase inhibitor sofosbuvir and antiviral ribavirin effective in HCV Genotypes 2 and 3 http://buff.ly/1o8pWr1 The relative risk reduction of 20% in breast-cancer mortality associated with mammography comes at a price. Abolish Mammography Screening Programs, says the SwissSwiss Medical Board. The report caused an uproar http://buff.ly/1o8qgGo In obese patients with uncontrolled DM2, intensive medical therapy plus bariatric surgery was better than drugs alone http://buff.ly/1o8qD3G First dialysis machine was made with aluminium from a bomber that was shot down and bits from an automobile engine http://buff.ly/1om861k At least 10% of adults and nearly all children who receive renal-replacement therapy have an inherited kidney disease http://buff.ly/1n8078E Kidney disease in farming communities worldwide remains a mystery : heavy metals and pesticides? indigenous herbs? OTC pain killers? chronic dehydration? http://buff.ly/1n80qjy Worldwide, chronic kidney disease affects 8—16% of population , number of deaths almost doubled in the past decade http://buff.ly/1n80MHa The articles were selected from Twitter and my RSS subscriptions. Please feel free to send suggestions for articles to clinicalcases AT gmail.com and you will receive acknowledgement in the next edition of this publication. "
...to discontinue the programme in metastatic, castration-resistant prostate cancer (CRPC) after deciding that orteronel's clinical profile was not "sufficient to move forward … given the availability of other therapies"
"With the development of vedolizumab, Takeda is building upon this heritage and expanding into innovative therapies with a new biologic treatment" Smith said
...general medicine Asit Parikh said many patients suffering from ulcerative colitis and Crohn's disease are eagerly awaiting new treatment options. "We are striving to accelerate the development of this drug to deliver this effective and highly anticipated treatment option for patients in Japan as soon as possible" Parikh said...

More Content

All (37) | News (20) | Reports (0) | Blogs (16) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Top medicine articles for July 2014 [Published Clinical Cases and Images: CasesBlog - Jul 23 2014]
MRC Technology Announces Humanization of Anti-T... [Published Select Science - Jul 22 2014]
New, broad-spectrum UC treatments available, in... [Published Orthopedics Today - Jul 18 2014]
Therapy of IBD: What to Expect in the Next Decade [Published General Medicine eJournal - Jul 17 2014]
European Medicines Agency recommends 39 medicin... [Published PharmaNews.eu - Jul 16 2014]
EMA: 39 human-use drug OKs in first-half 2014 [Published Pharma Times - Jul 10 2014]
Takeda's Entyvio available in UK for UC and Cro... [Published Pharma Times - Jul 09 2014]
Gut reaction [Published Drug Discovery News - Jul 09 2014]
Takeda's Entyvio available in UK for ulcerative... [Published Pharma Times - Jul 08 2014]
Treatment for ulcerative colitis and Crohn’s di... [Published Pharmacy Magazine - Jul 08 2014]
Treatment for ulcerative colitis and Crohn’s di... [Published PJ Online - Jul 08 2014]
Takeda drops prostate cancer drug in phase III [Published PMLive - Jun 20 2014]
Global crohn's disease market forecast to total... [Published PR inside - Jun 17 2014]
Entyvio available in US for treating ulcerative... [Published Orthopedics Today - Jun 16 2014]
ENTYVIO™ (vedolizumab) Now Available in the Uni... [Published PR Newswire: General Business - Jun 16 2014]
May's top stories: Bayer's $14.2bn Merck deal, ... [Published Pharmaceutical Technology - Jun 06 2014]
Takeda Receives European Commission Marketing A... [Published PRESSEMITTEILUNGEN - May 27 2014]
Takeda Receives European Commission Marketing A... [Published Nycomed News RSS feed - May 26 2014]
ENTYVIO (Vedolizumab) Injection, Powder, Lyophi... [Published DailyMed Drug Label Updates for the last seven ... - May 23 2014]
Takeda's Entyvio gets FDA approval to treat ulc... [Published PBR - News - May 21 2014]
Entyvio Approved for Ulcerative Colitis and Cro... [Published Yahoo! Health News - May 21 2014]
FDA Approves Takeda's Entyvio™ (vedolizumab) fo... [Published PR Newswire: Policy & Public Interest - May 20 2014]
FDA Approves Takeda's Entyvio™ (vedolizumab) fo... [Published Nycomed News RSS feed - May 20 2014]
Takeda's Entyvio Wins FDA OK for Severe Colitis [Published MedPageToday.com - medical news plus CME for ph ... - May 20 2014]
For Treatment of Ulcerative Colitis (UC), Great... [Published PR Newswire: General Business - Apr 21 2014]
EMA committee issues positive opinion for Taked... [Published Pharmaceutical Business Review - Mar 24 2014]
Takeda Receives Positive CHMP Opinion for Entyv... [Published Nycomed News RSS feed - Mar 23 2014]
Vedolizumab and IBD - IBD in the News [Published Mayo Clinic - YouTube - Feb 11 2014]
Research and Markets: Gastroenterology Thought ... [Published Business Wire Health News - Feb 11 2014]
Crohn's Disease Market to Show Modest Growth to... [Published Pharmaceutical Executive - Feb 04 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Top medicine articles for July 2014 [Published Clinical Cases and Images: CasesBlog - Jul 23 2014]
A collection of some interesting medical articles published recently: Migraines Linked to Increased Risk of 'Silent Strokes' http://buff.ly/1hTE5Ru Doctor’s Salaries Are Not the Big Cost - NYTimes http://buff.ly/QWe2lx  -- "There is a startling ...
ENTYVIO™ (vedolizumab) Now Available in the Uni... [Published PR Newswire: General Business - Jun 16 2014]
DEERFIELD, Ill., and OSAKA, Japan, June 16, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced the United States (U.S.) commercial availability of ...
Takeda Receives European Commission Marketing A... [Published PRESSEMITTEILUNGEN - May 27 2014]
Zurich And Osaka, Japan (ots/PRNewswire) – Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission (EC) has granted Marketing Authorisation for Entyvio(R) ...
Takeda Receives European Commission Marketing A... [Published Nycomed News RSS feed - May 26 2014]
Zurich, Switzerland, May 27th, 2014 and Osaka, Japan, May 28th, 2014 – Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission (EC) has granted Marketing ...
ENTYVIO (Vedolizumab) Injection, Powder, Lyophi... [Published DailyMed Drug Label Updates for the last seven ... - May 23 2014]
Updated Date: May 23, 2014 EST ...
1 2 3 4
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.